News | January 11, 2024
Lupin launches Varenicline Tablets in US
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
Mothers Against Vaping also highlights a recent study of young people at risk of experiencing significant respiratory symptoms after just 30 days of electronic cigarette and other new age gateway products use
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
The initiative will focus on advocating for cleaner air
The companies plan to start a pivotal Phase 3 trial in the coming months
Subscribe To Our Newsletter & Stay Updated
